Leishmaniasis: Omics Approaches to Understand its Biology from Molecule to Cell Level.

Leishmaniasis is the second deadliest vector-borne, neglected tropical zoonotic disease and is found in a variety of clinical forms based on genetic background. Its endemic type is present in tropical, sub-tropical and Mediterranean areas around the world which accounts for a lot of deaths every year. Currently, a variety of techniques are available for detection of leishmaniasis each technique having it's own pros and cons. The advancing next-generation sequencing (NGS) techniques are employed to find out novel diagnostic markers based on single nucleotide variants. A total of 274 NGS studies are available in European Nucleotide Archive (ENA) portal (https://www.ebi.ac.uk/ena/browser/home) that focused on wild-type and mutated Leishmania, differential gene expression, miRNA expression, and detection of aneuploidy mosaicism by omics approaches. These studies have provided insights into the population structure, virulence, and extensive structural variation, including known and suspected drug resistance loci, mosaic aneuploidy and hybrid formation under stressed conditions and inside the midgut of the sandfly. The complex interactions occurring within the parasite-host-vector triangle can be better understood by omics approaches. Further, advanced CRISPR technology allows researchers to delete and modify each gene individually to know the importance of genes in the virulence and survival of the disease-causing protozoa. In vitro generation of Leishmania hybrids are helping to understand the mechanism of disease progression in its different stages of infection. This review will give a comprehensive picture of the available omics data of various Leishmania spp. which helped to reveal the effect of climate change on the spread of its vector, the pathogen survival strategies, emerging antimicrobial resistance and its clinical importance.

Mosaicism in Human Health and Disease.

Mosaicism refers to the occurrence of two or more genomes in an individual derived from a single zygote. Germline mosaicism is a mutation that is limited to the gonads and can be transmitted to offspring. Somatic mosaicism is a postzygotic mutation that occurs in the soma, and it may occur at any developmental stage or in adult tissues. Mosaic variation may be classified in six ways: (a) germline or somatic origin, (b) class of DNA mutation (ranging in scale from single base pairs to multiple chromosomes), (c) developmental context, (d) body location(s), (e) functional consequence (including deleterious, neutral, or advantageous), and (f) additional sources of mosaicism, including mitochondrial heteroplasmy, exogenous DNA sources such as vectors, and epigenetic changes such as imprinting and X-chromosome inactivation. Technological advances, including single-cell and other next-generation sequencing, have facilitated improved sensitivity and specificity to detect mosaicism in a variety of biological contexts.

Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental Disorders.

Evidence from multiple laboratories has accumulated to show that mosaic neuronal aneuploidy and consequent apoptosis characterizes and may underlie neuronal loss in many neurodegenerative diseases, particularly Alzheimer's disease and frontotemporal dementia. Furthermore, several neurodevelopmental disorders, including Seckel syndrome, ataxia telangiectasia, Nijmegen breakage syndrome, Niemann-Pick type C, and Down syndrome, have been shown to also exhibit mosaic aneuploidy in neurons in the brain and in other cells throughout the body. Together, these results indicate that both neurodegenerative and neurodevelopmental disorders with apparently different pathogenic causes share a cell cycle defect that leads to mosaic aneuploidy in many cell types. When such mosaic aneuploidy arises in neurons in the brain, it promotes apoptosis and may at least partly underlie the cognitive deficits that characterize the neurological symptoms of these disorders. These findings have implications for both diagnosis and treatment/prevention.

An evidence-based scoring system for prioritizing mosaic aneuploid embryos following preimplantation genetic screening.

The aim of this study was to devise an evidence-based scoring system for prioritizing mosaic aneuploid embryos for transfer. A retrospective analysis was performed of all sequential cytogenetic and molecular results on chorionic villi samples (n = 72,472) and products of conception (n = 3806) analysed at a single centre. The likelihood that a mosaic aneuploidy detected in chorionic villi samples will involve the fetus, the incidence of clinically significant fetal uniparental disomy in the presence of a mosaic in chorionic villi and the chance of the mosaicism culminating in miscarriage were used to generate a scoring system for prioritizing mosaic aneuploid embryos detected by preimplantation genetic screening. A composite score was obtained for each individual mosaic aneuploidy after assignment of an individual risk score based on the incidence/likelihood of each adverse outcome. A final additional score was assigned to viable full or mosaic aneuploidies with a well-defined phenotype. The higher the composite score the lower the priority for embryo transfer. In conclusion, due to the paucity of prospective studies on the actual transfer of mosaic aneuploid embryos, we suggest using this evidence-based scoring system to provide a useful tool for clinicians, embryologists and patients.